Introduction {#sec1-1744806918770320}
============

Dysmenorrhea is commonly divided into two types: primary dysmenorrhea (PD) and secondary dysmenorrhea. PD is defined as the hypogastric pain originated from uterine without pathology during menstrual period which often occurs with the menarche or after the establishment of the ovulatory cycles of reproductive women and usually lasts two or three days during each period.^[@bibr1-1744806918770320]^ About 43%--91% adolescent females (under 20 years) are reported with PD and show a decreasing tendency as the age grows older.^[@bibr2-1744806918770320]^ Women experiencing severe PD will be debilitated to accomplish daily works, even absent from school or job. According to the previous studies, PD is often considered to be the result of abnormal prostaglandin release which leads to strong contracts of uterus and reduced oxygen supply to the uterus muscles.^[@bibr3-1744806918770320]^ Besides, unhealthy lifestyle (such as smoking, intemperance, and stressfulness) and family history may also have some negative influence on the symptoms of PD.^[@bibr4-1744806918770320]^

There are several treatments for PD like non-steroidal anti-inflammatory drugs (NSAIDs), oral contraceptive drugs, physical therapy interventions, Chinese traditional herbology, and so on.^[@bibr5-1744806918770320]^ Among them, NSAIDs are the first-line treatment.^[@bibr6-1744806918770320]^ There are many types of NSAIDs which are widely used as analgesics and anti-inflammatory agent through inhibiting cyclooxygenase (COX) enzymes including COX-1 and COX-2. The pain relieve ability of NSAIDs is mainly attributed to COX-2 enzymes inhibition---an important pathway related to hormone release and the process of inflammation, while their adverse effects (such as indigestion, headaches, and lethargy, which are considered to be the most concerning adverse effects in PD patients) are thought to be involved with the COX-1 enzymes inhibition.^[@bibr7-1744806918770320],[@bibr8-1744806918770320]^ Recently, selective COX-2 inhibitors have been established to mitigate the adverse effects in gastrointestinal tract and extend the drug effects with lower dose.^[@bibr9-1744806918770320]^ However, this kind of drug has been discovered to be related to increase the risk of heart complications if taken regularly and thus should be used more prudently.^[@bibr10-1744806918770320]^ Therefore, the requirement to evaluate efficacy and safety of NSAIDs is imminent for patients with PD.

To date, a large number of randomized controlled trials (RCTs) assessing the efficacy and safety of NSAIDs have been conducted,^[@bibr11-1744806918770320],[@bibr12-1744806918770320]^ and several published meta-analysis studies also compared the mainly used NSAIDs in the PD treatment.^[@bibr13-1744806918770320]^ However, the traditional meta-analysis only evaluates the direct comparison of pair-wised drugs, and there also exists conflict between different studies. Therefore, the purpose of this network meta-analysis is to indicate the relative efficacy and safety among most of the NSAIDs through not only direct but also indirect comparisons. We expect to draw a conclusion about the optimal treatment of PD by analyzing all published RCTs data of 13 individual NSAIDs.

Materials and methods {#sec2-1744806918770320}
=====================

Literature search and selection criteria {#sec3-1744806918770320}
----------------------------------------

We searched through China National Knowledge Internet, MEDLINE, and Embase to obtain the relevant RCTs comparing the efficacy and safety of NSAIDs for patients with PD using the key words "primary dysmenorrhea," "randomized controlled trial," "non-steroidal anti-inflammatory agents," "aspirin," "diclofenac," "flurbiprofen," "ibuprofen," "indomethacin," "ketoprofen," "mefenamic acid," "nimesulide," "piroxicam," "rofecoxib," "tiaprofenic acid," and "valdecoxib" in searching process (Supplemental Material). As for ketorolac and celecoxib, they were not been included in this network meta-analysis due to their serious adverse effects and main function which are often in the treatment in arthritis.

One RCT would be included in this network meta-analysis if it fulfilled each of the following criteria: (1) trials evaluating the efficacy or safety of NSAIDs in patients with PD, (2) trials that were designed as single-/double-/triple-blind, (3) trials covering at least one of the outcomes of interest, and (4) trials that using the same or close evaluation index (the way to describe the pain intensity difference and other outcomes). Two investigators independently reviewed abstracts and studies to evaluate the trial eligibility, and all conflicts were solved through discussion. There was no language restriction.

Outcome measures and data extraction {#sec4-1744806918770320}
------------------------------------

The primary efficacy outcome was pain relief (the proportion of patients who received effective or at least moderate pain relief), and the incidence of total treatment-related adverse effects like insomnia and gastrointestinal disease was added as a complementally safety outcome. As for secondary outcomes, we also assessed the requirements for additional rescue and pain intensity difference from baseline to end point. Using rescue medication or other medical assistance beyond the trials during specified time periods would be regarded as additional rescue. Pain intensity difference was defined as change scores of pain intensity rated by patients from baseline to end point. Assessment of the whole treatment from patients in each trail was also included in the secondary outcome; a higher score represents a better global assessment of patients.^[@bibr11-1744806918770320]^ However, since all these outcomes contained more than one score scale, we standardized each continuous data during analysis.

After excluding the studies that failed to fulfill the criteria, two independent reviewers screened each study and extracted relevant data concerning of the outcomes of this network meta-analysis. The main information was extracted including basic study background, enrollment numbers, detailed interventions, and outcome measures.

Statistical analysis {#sec5-1744806918770320}
--------------------

We used a Bayesian framework with STATA software (13.0) and R software (V3.3.1) for this network meta-analysis. One advantage of using the Bayesian framework was its ability to produce ranking probabilities which could be used to evaluate medications with respect to each end point. The forest plots showed the result of the meta-analysis included in this research. Furthermore, odds ratio (OR) and standardized mean difference were calculated for dichotomous outcomes and continuous outcomes, respectively, with 95% credible intervals (CrIs) between the two treatments on each outcome. Moreover, the surface under the cumulative ranking curve (SUCRA) was computed based on the outcomes above to estimate the performance of different interventions, and higher SUCRA represented better efficacy and safety. The inconsistency of each outcome between direct and indirect evidence was evaluated by node-splitting results and the heat plots.

Results {#sec6-1744806918770320}
=======

Study selection and characteristics of included trials {#sec7-1744806918770320}
------------------------------------------------------

A total of 1476 potentially relevant publications were identified by literature research. Then, 316 publications were removed as duplicates and 1039 publications were excluded due to the weak relevance to the subject. As a result, we retrieved 121 publications with full length into systematic review and included 70 studies with 72 RCTs of 5723 patients into our network meta-analysis due to the selection criteria as shown earlier.^[@bibr11-1744806918770320],[@bibr12-1744806918770320],[@bibr14-1744806918770320][@bibr15-1744806918770320][@bibr16-1744806918770320][@bibr17-1744806918770320][@bibr18-1744806918770320][@bibr19-1744806918770320][@bibr20-1744806918770320][@bibr21-1744806918770320][@bibr22-1744806918770320][@bibr23-1744806918770320][@bibr24-1744806918770320][@bibr25-1744806918770320][@bibr26-1744806918770320][@bibr27-1744806918770320][@bibr28-1744806918770320][@bibr29-1744806918770320][@bibr30-1744806918770320][@bibr31-1744806918770320][@bibr32-1744806918770320][@bibr33-1744806918770320][@bibr34-1744806918770320][@bibr35-1744806918770320][@bibr36-1744806918770320][@bibr37-1744806918770320][@bibr38-1744806918770320][@bibr39-1744806918770320][@bibr40-1744806918770320][@bibr41-1744806918770320][@bibr42-1744806918770320][@bibr43-1744806918770320][@bibr44-1744806918770320][@bibr45-1744806918770320][@bibr46-1744806918770320][@bibr47-1744806918770320][@bibr48-1744806918770320][@bibr49-1744806918770320][@bibr50-1744806918770320][@bibr51-1744806918770320][@bibr52-1744806918770320][@bibr53-1744806918770320][@bibr54-1744806918770320][@bibr55-1744806918770320][@bibr56-1744806918770320][@bibr57-1744806918770320][@bibr58-1744806918770320][@bibr59-1744806918770320][@bibr60-1744806918770320][@bibr61-1744806918770320][@bibr62-1744806918770320][@bibr63-1744806918770320][@bibr64-1744806918770320][@bibr65-1744806918770320][@bibr66-1744806918770320][@bibr67-1744806918770320][@bibr68-1744806918770320][@bibr69-1744806918770320][@bibr70-1744806918770320][@bibr71-1744806918770320][@bibr72-1744806918770320][@bibr73-1744806918770320][@bibr74-1744806918770320][@bibr75-1744806918770320][@bibr76-1744806918770320][@bibr77-1744806918770320][@bibr78-1744806918770320][@bibr79-1744806918770320][@bibr80-1744806918770320]--[@bibr81-1744806918770320]^ The flowchart of the whole process is shown in [Figure 1](#fig1-1744806918770320){ref-type="fig"}. Among the 70 studies, 18 trials were three-arm studies, 48 trials were conducted between one intervention and placebo, and 6 trials were between two different interventions. All trials included 13 drugs as follows: aspirin, diclofenac, flurbiprofen, ibuprofen, indomethacin, ketoprofen, mefenamic acid, mefenamic, nimesulide, piroxicam, rofecoxib, tiaprofenic acid, and valdecoxib. The network structure is shown in [Figure 1](#fig1-1744806918770320){ref-type="fig"} and Figure S1, the circle area represented the enrollment of each treatment, and lines width showed the number of compared trials. Main characteristics of the included publications and trials are presented in [Table 1](#table1-1744806918770320){ref-type="table"}.

![Flowchart and network structure for pain relief. The network plots show direct comparison of different drugs, with node size corresponding to the sample size. The number of included studies for specific direct comparison decides the thickness of solid lines.](10.1177_1744806918770320-fig1){#fig1-1744806918770320}

###### 

Main characteristics of included studies.

![](10.1177_1744806918770320-table1)

  Trial                                                  Country        Type              Blinding       No.    Study period   Intervention 1     Intervention 2   Intervention 3                                                                                                                                                       
  ------------------------------------------------------ -------------- ----------------- -------------- ------ -------------- ------------------ ---------------- ---------------------------------------------------------------- ------------------ ----- ---------------------------------------------------------------- --------- -----
  Three-arm trials                                                                                                                                                                                                                                                                                                                      
   Daniels et al.^[@bibr72-1744806918770320]^            USA            RCT, crossover    Double-blind   120    4 cycles       Valdecoxib         183              20 mg/40 mg                                                      Naproxen           93    550 mg                                                           Placebo   94
   Daniels et al.^[@bibr67-1744806918770320]^            USA            RCT, crossover    Double-blind   118    4 cycles       Valdecoxib         192              20 mg/40 mg                                                      Naproxen           96    550 mg                                                           Placebo   96
   Morrison et al.^[@bibr66-1744806918770320]^           USA            RCT, parallel     Double-blind   127    --             Rofecoxib          233              25 mg + 25 mg/50 mg +25 mg                                       Naproxen           122   550 mg                                                           Placebo   118
   Marchini et al.^[@bibr62-1744806918770320]^           Italy          RCT, crossover    Double-blind   60     3 cycles       Ibuprofen          56               400 mg                                                           Diclofenac         56    50 mg                                                            Placebo   57
   Tilyard and Dovey^[@bibr61-1744806918770320]^         New Zealand    RCT, crossover    Double-blind   50     8 cycles       Mefenamic acid     40               250 mg                                                           Tiaprofenic acid   40    200 mg                                                           Placebo   40
   Mehlisch^[@bibr60-1744806918770320]^                  USA            RCT, crossover    Double-blind   70     3 cycles       Ketoprofen         180              25-mg LD/50 mg/75 mg                                             Naproxen           60    500-mg LD +250 mg                                                Placebo   60
   Pasquale et al.^[@bibr56-1744806918770320]^           USA            RCT, parallel     Double-blind   74     1 cycle        Piroxicam          39               20 mg/40-mg 1d +20 mg/40 mg                                      Ibuprofen          15    400 mg                                                           Placebo   11
   Palmisano and Lamb^[@bibr55-1744806918770320]^        USA            RCT, crossover    Double-blind   36     3 cycles       Ketoprofen         36               150 mg                                                           Ibuprofen          36    800 mg                                                           Placebo   36
   Mehlisch^[@bibr54-1744806918770320]^                  USA            RCT, crossover    Double-blind   43     3 cycles       Ketoprofen         26               150 mg                                                           Ibuprofen          26    800 mg                                                           Placebo   26
   Shapiro^[@bibr50-1744806918770320]^                   USA            RCT, crossover    Double-blind   43     4 cycles       Flurbiprofen       43               50 mg                                                            Aspirin            43    650 mg                                                           Placebo   43
   Kauppila et al.^[@bibr49-1744806918770320]^           Finland        RCT, crossover    Double-blind   42     6 cycles       Tiaprofenic acid   31               200 mg                                                           Naproxen           31    250 mg                                                           Placebo   31
   Roy^[@bibr43-1744806918770320]^                       USA            RCT, crossover    Double-blind   48     2 cycles       Mefenamic acid     48               --                                                               Ibuprofen          48                                                                     Placebo   48
   Gookin et al.^[@bibr40-1744806918770320]^             USA            RCT, crossover    Double-blind   42     3 cycles       Ibuprofen          31               400 mg                                                           Indomethacin       31    25 mg                                                            Placebo   31
   Delia et al.^[@bibr37-1744806918770320]^              USA            RCT, crossover    Double-blind   59     3 cycles       Flurbiprofen       59               50 mg                                                            Aspirin            59    650 mg                                                           Placebo   59
   Rosenwaks et al.^[@bibr36-1744806918770320]^          USA            RCT, crossover    Double-blind   32     2 cycles       Naproxen           23               275 mg                                                           Aspirin            23    325 mg                                                           Placebo   16
   Pogmore and Filshie^[@bibr33-1744806918770320]^       UK             RCT, crossover    Double-blind   80     3 months       Flurbiprofen       39               50 mg                                                            Aspirin            39    500 mg                                                           Placebo   39
   Pulkkinen and Csapo^29^                               USA            RCT, crossover    Single-blind   15     2 cycles       Naproxen           15               1100 mg                                                          Ibuprofen          15    800 mg                                                           Placebo   30
   Kajanoja^[@bibr17-1744806918770320]^                  Finland        RCT, crossover    Double-blind   47     6 cycles       Indomethacin       90               25 mg                                                            Aspirin            89    500 mg                                                           Placebo   90
  Two-arm trials                                                                                                                                                                                                                                                                                                                        
   Salmalian et al.^[@bibr81-1744806918770320]^          Iran           RCT, parallel     Triple-blind   56     2 cycles       Ibuprofen          24               200 mg                                                           Placebo            28                                                                               
   Iacovides et al.^[@bibr12-1744806918770320]^          South Africa   RCT, crossover    Double-blind   24     2 cycles       Diclofenac         24               50 mg                                                            Placebo            24                                                                               
   Heidarifar et al.^[@bibr80-1744806918770320]^         Iran           RCT, parallel     Double-blind   50     2 cycles       Mefenamic acid     24               250 mg                                                           Placebo            23                                                                               
   Nahid et al.^[@bibr79-1744806918770320]^              Iran           RCT, parallel     Double-blind   120    3 cycles       Mefenamic acid     55               250 mg                                                           Placebo            51                                                                               
   Daniels et al.^[@bibr77-1744806918770320]^            USA            RCT, crossover    Double-blind   149    3 cycles       Naproxen           123              550 mg                                                           Placebo            122                                                                              
                                                                        RCT, crossover    Double-blind   154    3 cycles       Naproxen           120              550 mg                                                           Placebo            121                                                                              
   Iacovides et al.^[@bibr78-1744806918770320]^          USA            RCT, crossover    Double-blind   10     --             Diclofenac         10               150 mg                                                           Placebo            10                                                                               
   Chantler et al.^[@bibr76-1744806918770320]^           South Africa   RCT, crossover    Double-blind   12     3 cycles       Diclofenac         12               100 mg                                                           Placebo            12                                                                               
   Daniels et al.^[@bibr11-1744806918770320]^            USA            RCT, crossover    Double-blind   135    3 cycles       Naproxen           124              500 mg                                                           Placebo            125                                                                              
   Doubova et al.^[@bibr75-1744806918770320]^            Mexico         RCT, parallel     Double-blind   88     --             Ibuprofen          46               1200 mg                                                          Placebo            42                                                                               
   Dawood and  Khan-Dawood^[@bibr74-1744806918770320]^   USA            RCT, crossover    Double-blind   12     3 cycles       Ibuprofen          10               400 mg                                                           Placebo            10                                                                               
   Letzel et al.^[@bibr73-1744806918770320]^             Germany        RCT, crossover    Double-blind   127    3 cycles       Naproxen           92               500 mg                                                           Placebo            93                                                                               
   De Mello et al.^[@bibr71-1744806918770320]^           Brazil         RCT, parallel     Double-blind   337    3 cycles       Meloxicam          190              7.5 mg/15 mg                                                     Mefenamic acid     97    500 mg                                                                     
   Bitner et al.^[@bibr70-1744806918770320]^             USA            RCT, crossover    Double-blind   109    3 cycles       Naproxen           89               500 mg                                                           Placebo            88                                                                               
   Malmstrom et al.^[@bibr69-1744806918770320]^          USA            RCT, crossover    Double-blind   73     3 cycles       Naproxen           60               550 mg                                                           Placebo            60                                                                               
   Milsom et al.^[@bibr68-1744806918770320]^             UK             RCT, crossover    Double-blind   1242   3 cycles       Naproxen           412              400 mg/200 mg                                                    Placebo            206                                                                              
   Di Girolamo et al.^[@bibr65-1744806918770320]^        Argentina      RCT, crossover    Double-blind   24     3 cycles       Ibuprofen          24               400 mg                                                           Placebo            24                                                                               
   Ezcurdia et al.^[@bibr64-1744806918770320]^           Spain          RCT, crossover    Double-blind   52     --             Ketoprofen         44               50 mg                                                            Placebo            44                                                                               
   Mehlisch and  Fulmer^[@bibr63-1744806918770320]^      USA            RCT, crossover    Double-blind   54     4 cycles       Naproxen           53               550 mg                                                           Placebo            51                                                                               
   Fedele et al.^[@bibr59-1744806918770320]^             Italy          RCT, parallel     Double-blind   55     4 cycles       Naproxen           14               250 mg                                                           Placebo            31                                                                               
   Andersch and  Milsom^[@bibr58-1744806918770320]^      Sweden         RCT, crossover    Double-blind   60     4 cycles       Flurbiprofen       57               50 mg                                                            Naproxen           57    250 mg                                                                     
   Akerlund and  Stromberg^[@bibr57-1744806918770320]^   Sweden         RCT, crossover    Double-blind   42     2 cycles       Ketoprofen         39               100 mg                                                           Naproxen           39    500 mg                                                                     
   Pulkkinen^[@bibr53-1744806918770320]^                 Finland        RCT, crossover    Double-blind   14     4 cycles       Nimesulide         28               100 mg                                                           Placebo            18                                                                               
   Kapadia^[@bibr52-1744806918770320]^                   UK             RCT, parallel     Single-blind   56     3 cycles       Naproxen           28               550 mg                                                           Ibuprofen          23    400 mg                                                                     
   Fraser and McCarron^[@bibr51-1744806918770320]^       Australia      RCT, crossover    Double-blind   38     6 cycles       Ibuprofen          38               400 mg                                                           Placebo            38                                                                               
   Wilhelmsson et al.^[@bibr48-1744806918770320]^        Sweden         RCT, crossover    Double-blind   83     --             Piroxicam          83               40 mg + 20 mg                                                    Naproxen           83    1000 mg                                                                    
   Saltveit^[@bibr47-1744806918770320]^                  Norway         RCT, crossover    Double-blind   92     4 months       Piroxicam          92               20 mg                                                            Placebo            92                                                                               
   Osathanondh et al.^[@bibr46-1744806918770320]^        USA            RCT, parallel     Double-blind   85     6 months       Aspirin            24               650 mg                                                           Placebo            24                                                                               
   Milsom and Andersch^[@bibr45-1744806918770320]^       Sweden         RCT, crossover    Double-blind   60     4 cycles       Ibuprofen          57               6^[a](#table-fn2-1744806918770320){ref-type="table-fn"}^200 mg   Naproxen           57    4^[a](#table-fn2-1744806918770320){ref-type="table-fn"}^125 mg             
   Rondel et al.^[@bibr44-1744806918770320]^             Germany        RCT, crossover    Double-blind   12     4 cycles       Nimesulide         12               200 mg                                                           Placebo            12                                                                               
   Lalos and Nilsson^[@bibr42-1744806918770320]^         Sweden         RCT, crossover    Double-blind   21     4 periods      Naproxen           20               250 mg                                                           Placebo            20                                                                               
   Jacobson et al.^[@bibr41-1744806918770320]^           Sweden         RCT, crossover    Double-blind   39     4 cycles       Naproxen           39               500 mg + 250 mg                                                  Placebo            39                                                                               
   Gleeson and Sorbie^[@bibr39-1744806918770320]^        Canada         RCT, crossover    Double-blind   27     6 cycles       Ketoprofen         27               --                                                               Placebo            27                                                                               
   Chan et al.^[@bibr38-1744806918770320]^               USA            RCT, cross-over   Double-blind   12     3 cycles       Naproxen           12               275 mg                                                           Placebo            12                                                                               
   Riihiluoma et al.^[@bibr35-1744806918770320]^         Finland        RCT, crossover    Double-blind   35     4 cycles       Diclofenac         58               25 mg                                                            Placebo            57                                                                               
   Chan et al.^[@bibr34-1744806918770320]^               USA            RCT, crossover    Double-blind   14     --             Naproxen           20               550 mg + 275 mg                                                  Placebo            20                                                                               
   Morrison et al.^[@bibr32-1744806918770320]^           USA            RCT, crossover    Triple-blind   55     3 cycles       Ibuprofen          51               400 mg                                                           Placebo            51                                                                               
   Hamann^[@bibr30-1744806918770320]^                    Denmark        RCT, crossover    Double-blind   30     4 cycles       Naproxen           26               250 mg                                                           Placebo            26                                                                               
   Henzl et al.^[@bibr31-1744806918770320]^              --             RCT, parallel     Double-blind   431    --             Naproxen           212              --                                                               Placebo            219                                                                              
   Elder and Kapadia^[@bibr24-1744806918770320]^         --             RCT, crossover    Double-blind   32     6 cycles       Indomethacin       32               25 mg                                                            Placebo            32                                                                               
   Pulkkinen 1979                                        USA            RCT, crossover    Single-blind   15     2 cycles       Ibuprofen          15               400 mg                                                           Placebo            15                                                                               
   Morrison and  Jennings^[@bibr27-1744806918770320]^    USA            RCT, crossover    Double-blind   32     4 cycles       Indomethacin       16               25 mg                                                            Placebo            16                                                                               
   Larkin et al.^[@bibr26-1744806918770320]^             USA            RCT, crossover    Double-blind   22     --             Ibuprofen          22               400 mg                                                           Placebo            22                                                                               
   Jacobson et al.^[@bibr25-1744806918770320]^           Sweden         RCT, parallel     Double-blind   34     2 cycles       Naproxen           16               250--500 mg                                                      Placebo            18                                                                               
   Dandenell et al.^[@bibr23-1744806918770320]^          Sweden         RCT, parallel     Double-blind   97     2 cycles       Naproxen           48               250 mg                                                           Placebo            49                                                                               
   Budoff^[@bibr22-1744806918770320]^                    USA            RCT, crossover    Double-blind   46     6 cycles       Mefenamic acid     23               250 mg                                                           Placebo            21                                                                               
   Sande et al.^[@bibr21-1744806918770320]^              Norway, USA    RCT, parallel     Double-blind   32     3 cycles       Naproxen           15               275 mg                                                           Placebo            17                                                                               
   Pulkkinen and  Csapo^[@bibr20-1744806918770320]^      Finland, USA   RCT, crossover    Single-blind   12     --             Ibuprofen          12               800 mg                                                           Placebo            12                                                                               
   Pauls^[@bibr19-1744806918770320]^                     Canada         RCT, parallel     Double-blind   17     3 cycles       Naproxen           9                275 mg                                                           Placebo            8                                                                                
   Lundstrom^[@bibr18-1744806918770320]^                 --             RCT, crossover    Double-blind   52     6 cycles       Naproxen           26               550 mg + 275 mg +275 mg                                          Placebo            26                                                                               
   Janbu et al.^[@bibr16-1744806918770320]^              Norway         RCT, crossover    Double-blind   30     3 cycles       Aspirin            30               500 mg                                                           Placebo            30                                                                               
   Hanson et al.^[@bibr15-1744806918770320]^             USA            RCT, parallel     Double-blind   64     3 cycles       Naproxen           29               275 mg                                                           Placebo            35                                                                               
   Henzl et al.^[@bibr14-1744806918770320]^              USA            RCT, parallel     Double-blind   20     4 cycles       Naproxen           10               550 mg + 275 mg                                                  Placebo            10                                                                               
                                                                        RCT, parallel     Double-blind   23     4 cycles       Naproxen           12               550 mg + 275 mg                                                  Placebo            12                                                                               

Note: RCT: randomized controlled trials.

^a^The article does not mention the type of dysmenorrhea. 1d: Day 1.

Overall outcomes {#sec8-1744806918770320}
----------------

All the data of this network meta-analysis results for five outcomes are presented in [Tables 2](#table2-1744806918770320){ref-type="table"}[](#table3-1744806918770320){ref-type="table"} to [4](#table4-1744806918770320){ref-type="table"} and the forest plots in [Figure 2](#fig2-1744806918770320){ref-type="fig"} and Figures S2 to S5. For the primary outcomes shown in [Table 2](#table2-1744806918770320){ref-type="table"}, the comparison between each pair of drugs was evaluated. As for pain relief, all drugs except aspirin were superior to placebo. When aspirin was compared with other drugs, the results showed that it was worse than most of the drugs such as diclofenac (OR = 0.28, 95% CrI = 0.08--0.86), indomethacin (OR = 0.21, 95% CrIs = 0.07--0.58), and flurbiprofen (OR = 0.10, 95% CrI = 0.03--0.29), and so on. On the other hand, considering the safety, tiaprofenic acid and mefenamic acid were noticeable in low incidence of adverse effects, and indomethacin revealed higher adverse effects than any other drugs.

###### 

Network meta-analysis results for pain relief (lower left) and adverse effects (upper right).

![](10.1177_1744806918770320-table2)

  ------------------- ------------------- -------------------- -------------------- ------------------- -------------------- ------------------- -------------------- ------------------- ------------------- -------------------- ------------------- ---------------------- --------------------
  **Placebo**         0.99 (0.59, 1.65)   3.22 (0.97, 12.55)   1.82 (1.04, 3.29)    0.90 (0.56, 1.45)   3.60 (1.68, 7.46)    0.73 (0.36, 1.46)   0.66 (0.31, 1.39)    1.08 (0.87, 1.38)   --                  1.14 (0.56, 2.20)    1.17 (0.64, 2.23)   0.45 (0.08, 1.68)      1.22 (0.75, 2.05)
  0.57 (0.29, 1.11)   **Aspirin**         3.25 (0.84, 14.15)   1.86 (1.00, 3.46)    0.91 (0.42, 1.82)   3.60 (1.60, 8.08)    0.74 (0.32, 1.75)   0.65 (0.27, 1.68)    1.09 (0.64, 1.90)   --                  1.14 (0.48, 2.69)    1.19 (0.54, 2.66)   0.46 (0.07, 1.93)      1.23 (0.61, 2.53)
  0.16 (0.06, 0.39)   0.28 (0.08, 0.86)   **Diclofenac**       0.57 (0.13, 2.27)    0.28 (0.07, 0.91)   1.13 (0.22, 4.57)    0.23 (0.05, 0.93)   0.20 (0.05, 0.83)    0.34 (0.09, 1.15)   --                  0.35 (0.08, 1.40)    0.36 (0.08, 1.48)   0.14 (0.02, 0.83)      0.38 (0.09, 1.42)
  0.06 (0.02, 0.17)   0.10 (0.03, 0.29)   0.35 (0.09, 1.55)    **Flurbiprofen**     0.49 (0.21, 1.05)   1.93 (0.77, 4.85)    0.39 (0.17, 1.00)   0.35 (0.14, 0.91)    0.59 (0.33, 1.07)   --                  0.61 (0.25, 1.48)    0.64 (0.28, 1.49)   0.25 (0.04, 1.05)      0.66 (0.32, 1.42)
  0.18 (0.11, 0.30)   0.32 (0.14, 0.73)   1.14 (0.42, 3.22)    3.19 (0.95, 10.70)   **Ibuprofen**       4.06 (1.63, 9.30)    0.82 (0.35, 1.84)   0.73 (0.32, 1.67)    1.21 (0.76, 2.05)   --                  1.28 (0.55, 2.83)    1.32 (0.61, 2.86)   0.51 (0.09, 1.95)      1.36 (0.70, 2.69)
  0.12 (0.05, 0.29)   0.21 (0.07, 0.58)   0.73 (0.20, 2.75)    2.05 (0.50, 8.25)    0.64 (0.23, 1.77)   **Indomethacin**     0.20 (0.08, 0.57)   0.18 (0.07, 0.55)    0.30 (0.14, 0.67)   --                  0.32 (0.11, 0.85)    0.33 (0.12, 0.90)   0.13 (0.02, 0.57)      0.34 (0.14, 0.85)
  0.15 (0.07, 0.28)   0.25 (0.10, 0.64)   0.90 (0.30, 2.94)    2.56 (0.71, 9.03)    0.79 (0.37, 1.75)   1.23 (0.41, 3.86)    **Ketoprofen**      0.90 (0.32, 2.59)    1.48 (0.73, 3.06)   --                  1.57 (0.57, 4.06)    1.60 (0.64, 4.10)   0.63 (0.10, 2.89)      1.67 (0.72, 3.94)
  0.16 (0.06, 0.40)   0.28 (0.09, 0.87)   0.97 (0.27, 3.78)    2.77 (0.66, 11.59)   0.86 (0.31, 2.39)   1.34 (0.36, 5.10)    1.07 (0.35, 3.35)   **Mefenamic acid**   1.67 (0.76, 3.56)   --                  1.73 (0.63, 4.53)    1.79 (0.70, 4.71)   0.70 (0.11, 2.89)      1.86 (0.77, 4.66)
  0.18 (0.12, 0.25)   0.31 (0.15, 0.64)   1.09 (0.41, 3.03)    3.10 (0.98, 9.49)    0.97 (0.53, 1.77)   1.51 (0.56, 4.06)    1.21 (0.59, 2.41)   1.13 (0.41, 3.00)    **Naproxen**        --                  1.05 (0.51, 2.01)    1.08 (0.58, 2.03)   0.41 (0.07, 1.57)      1.13 (0.68, 1.88)
  0.21 (0.05, 0.92)   0.37 (0.07, 1.88)   1.30 (0.23, 7.77)    3.67 (0.56, 23.34)   1.15 (0.23, 5.64)   1.79 (0.30, 10.38)   1.43 (0.27, 7.39)   1.34 (0.22, 7.85)    1.19 (0.25, 5.47)   **Nimesulide**      --                   --                  --                     --
  0.08 (0.02, 0.28)   0.15 (0.03, 0.59)   0.53 (0.11, 2.51)    1.49 (0.28, 7.46)    0.46 (0.12, 1.73)   0.72 (0.15, 3.35)    0.58 (0.14, 2.29)   0.54 (0.11, 2.51)    0.48 (0.14, 1.60)   0.41 (0.06, 2.83)   **Piroxicam**        1.03 (0.43, 2.66)   0.40 (0.06, 1.84)      1.07 (0.48, 2.53)
  0.21 (0.05, 0.99)   0.37 (0.07, 2.01)   1.31 (0.23, 8.41)    3.71 (0.57, 24.53)   1.16 (0.23, 5.99)   1.80 (0.30, 11.36)   1.46 (0.27, 7.85)   1.35 (0.22, 8.33)    1.20 (0.25, 5.99)   1.02 (0.12, 8.94)   2.48 (0.36, 19.11)   **Rofecoxib**       0.38 (0.07, 1.65)      1.04 (0.47, 2.27)
  0.10 (0.03, 0.30)   0.17 (0.04, 0.63)   0.59 (0.13, 2.69)    1.67 (0.33, 8.17)    0.52 (0.14, 1.84)   0.81 (0.18, 3.67)    0.65 (0.17, 2.46)   0.61 (0.15, 2.39)    0.54 (0.16, 1.77)   0.45 (0.07, 3.06)   1.13 (0.21, 6.17)    0.45 (0.06, 3.06)   **Tiaprofenic acid**   2.72 (0.66, 14.59)
  0.23 (0.09, 0.58)   0.41 (0.13, 1.26)   1.46 (0.41, 5.64)    4.10 (0.98, 16.78)   1.28 (0.45, 3.67)   1.99 (0.54, 7.46)    1.62 (0.53, 4.90)   1.49 (0.40, 5.53)    1.34 (0.54, 3.35)   1.13 (0.20, 6.62)   2.77 (0.63, 12.94)   1.11 (0.18, 6.62)   2.46 (0.57, 10.91)     **Valdecoxib**
  ------------------- ------------------- -------------------- -------------------- ------------------- -------------------- ------------------- -------------------- ------------------- ------------------- -------------------- ------------------- ---------------------- --------------------

Note: The column treatments are compared against row treatments.

###### 

Network meta-analysis results for additional rescue (lower left) and assessment (upper right).

![](10.1177_1744806918770320-table3)

  --------------------- --------------------- -------------------- ---------------------- --------------------- ---------------------- -------------------- ---------------------- --------------------- -------------------- ---------------------- ---------------------- ---------------------
  **Placebo**           −0.12 (−0.93, 0.68)   --                   −0.69 (−1.29, −0.10)   −0.65 (−1.42, 0.12)   −0.91 (−1.73, −0.10)   --                   −0.71 (−1.11, −0.30)   −1.05 (−2.33, 0.23)   --                   −0.86 (−1.62, −0.11)   --                     −0.60 (−1.60, 0.40)
  1.19 (0.52, 2.64)     **Aspirin**           --                   −0.57 (−1.55, 0.40)    −0.53 (−1.47, 0.41)   −0.79 (−1.93, 0.35)    --                   −0.58 (−1.48, 0.31)    −0.93 (−2.44, 0.58)   --                   −0.74 (−1.84, 0.36)    --                     −0.48 (−1.76, 0.81)
  4.10 (1.49, 11.59)    3.46 (1.15, 11.25)    **Flurbiprofen**     --                     --                    --                     --                   --                     --                    --                   --                     --                     --
  7.46 (3.42, 17.12)    6.30 (2.08, 20.09)    1.80 (0.50, 6.69)    **Ibuprofen**          0.04 (−0.83, 0.92)    −0.22 (−1.12, 0.69)    --                   −0.01 (−0.73, 0.71)    −0.36 (−1.77, 1.05)   --                   −0.17 (−1.13, 0.79)    --                     0.09 (−1.07, 1.26)
  --                    --                    --                   --                     **Indomethacin**      −0.26 (−1.36, 0.84)    --                   −0.05 (−0.92, 0.81)    −0.40 (−1.89, 1.09)   --                   −0.21 (−1.29, 0.87)    --                     0.05 (−1.21, 1.31)
  2.27 (0.55, 9.78)     1.92 (0.38, 10.38)    0.55 (0.10, 3.22)    0.31 (0.06, 1.58)      --                    **Ketoprofen**         --                   0.21 (−0.70, 1.11)     −0.14 (−1.66, 1.38)   --                   0.05 (−1.06, 1.16)     --                     0.31 (−0.98, 1.60)
  8.67 (2.2, 34.81)     7.32 (1.51, 37.71)    2.10 (0.38, 11.70)   1.16 (0.23, 5.75)      --                    3.82 (0.5, 27.66)      **Mefenamic acid**   --                     --                    --                   --                     --                     --
  3.16 (2.29, 4.66)     2.66 (1.17, 6.55)     0.77 (0.28, 2.20)    0.42 (0.19, 0.98)      --                    1.39 (0.35, 5.58)      0.36 (0.09, 1.55)    **Naproxen**           −0.35 (−1.69, 1.00)   --                   −0.16 (−0.96, 0.64)    --                     0.11 (−0.9, 1.11)
  --                    --                    --                   --                     --                    --                     --                   --                     **Nimesulide**        --                   0.19 (−1.30, 1.67)     --                     0.45 (−1.17, 2.08)
  3.67 (1.19, 11.70)    3.10 (0.79, 12.81)    0.90 (0.19, 4.14)    0.49 (0.13, 1.79)      --                    1.62 (0.25, 10.18)     0.43 (0.07, 2.53)    1.16 (0.35, 3.82)      --                    **Piroxicam**        --                     --                     --
  1.22 (0.45, 3.46)     1.03 (0.29, 3.90)     0.30 (0.07, 1.25)    0.17 (0.05, 0.59)      --                    0.54 (0.09, 3.00)      0.14 (0.03, 0.79)    0.39 (0.14, 1.05)      --                    0.33 (0.07, 1.54)    **Rofecoxib**          --                     0.26 (−0.97, 1.50)
  11.25 (2.01, 95.58)   9.58 (1.43, 94.63)    2.75 (0.37, 28.79)   1.52 (0.23, 14.44)     --                    5.00 (0.52, 62.18)     1.32 (0.14, 15.96)   3.56 (0.62, 29.96)     --                    3.10 (0.39, 33.78)   9.30 (1.25, 95.58)     **Tiaprofenic acid**   --
  2.69 (1.30, 5.87)     2.27 (0.79, 7.10)     0.65 (0.19, 2.32)    0.36 (0.12, 1.06)      --                    1.19 (0.24, 5.81)      0.31 (0.07, 1.52)    0.85 (0.39, 1.79)      --                    0.73 (0.19, 2.89)    2.20 (0.63, 7.61)      0.24 (0.03, 1.58)      **Valdecoxib**
  --------------------- --------------------- -------------------- ---------------------- --------------------- ---------------------- -------------------- ---------------------- --------------------- -------------------- ---------------------- ---------------------- ---------------------

Note: The column treatments are compared against row treatments.

###### 

Network meta-analysis results for secondary pain intensity difference.

![](10.1177_1744806918770320-table4)

  ---------------------- --------------------- --------------------- -------------------- --------------------- ------------------ -------------------- --------------------- -------------------- ----------------------
  Placebo                                                                                                                                                                                          
  −0.02 (−1.94, 1.91)    **Aspirin**                                                                                                                                                               
  −1.86 (−3.89, 0.17)    −1.84 (−4.64, 0.95)   **Diclofenac**                                                                                                                                      
  −1.99 (−5.00, 1.03)    −1.97 (−5.55, 1.60)   −0.13 (−3.76, 3.51)   **Flurbiprofen**                                                                                                              
  −1.56 (−2.92, −0.20)   −1.54 (−3.90, 0.81)   0.30 (−2.14, 2.75)    0.43 (−2.64, 3.50)   **Ibuprofen**                                                                                            
  --                     --                    --                    --                   --                    **Indomethacin**                                                                   
  −1.62 (−4.33, 1.09)    −1.61 (−4.93, 1.72)   0.24 (−3.15, 3.62)    0.37 (−3.69, 4.42)   −0.06 (−3.10, 2.97)   --                 **Ketoprofen**                                                  
  −0.95 (−2.52, 0.62)    −0.94 (−3.42, 1.55)   0.91 (−1.66, 3.47)    1.04 (−2.36, 4.43)   0.60 (−1.47, 2.68)    --                 0.67 (−2.46, 3.80)   **Mefenamic acid**                         
  −1.00 (−2.36, 0.35)    −0.98 (−3.34, 1.37)   0.86 (−1.58, 3.30)    0.99 (−1.71, 3.68)   0.56 (−0.91, 2.03)    --                 0.62 (−2.41, 3.65)   −0.05 (−2.12, 2.02)   **Naproxen**         
  −0.88 (−3.34, 1.59)    −0.86 (−3.99, 2.27)   0.98 (−2.21, 4.18)    1.11 (−2.78, 5.01)   0.68 (−2.14, 3.50)    --                 0.75 (−2.92, 4.41)   0.08 (−2.39, 2.54)    0.12 (−2.69, 2.94)   **Tiaprofenic acid**
  ---------------------- --------------------- --------------------- -------------------- --------------------- ------------------ -------------------- --------------------- -------------------- ----------------------

Note: The column treatments are compared against row treatments.

![Forest plots for pain relief using ORs and 95% CrIs. OR: odds ratios; Crls: credible intervals.](10.1177_1744806918770320-fig2){#fig2-1744806918770320}

The secondary outcomes of this network meta-analysis are listed in [Tables 3](#table3-1744806918770320){ref-type="table"} and [4](#table4-1744806918770320){ref-type="table"}. According to the outcomes, most of the drugs needed less additional rescue after assigned interventions compared with placebo. Nevertheless, aspirin still required additional rescue when compared with the majority of other drugs. As for assessment of the whole treatment, ketoprofen, naproxen, rofecoxib, and ibuprofen got higher score significantly than placebo. In addition, ibuprofen performed better than placebo in pain intensity difference.

Ranking conclusion {#sec9-1744806918770320}
------------------

The results of SUCRA under five outcomes are shown in [Table 5](#table5-1744806918770320){ref-type="table"}. According to the standing list of the primary outcomes, flurbiprofen (SUCRA: 0.904) ranked first in pain relief, successively followed by piroxicam (SUCRA: 0.787), tiaprofenic acid (SUCRA: 0.751), and indomethacin (SUCRA: 0.678). Besides, aspirin was indicated to be the worst among all of the NSAIDs in pain relief. In terms of adverse effects, the lower SUCRA suggested the higher incidence of adverse effects. Tiaprofenic acid (SUCRA: 0.872) performed best with mefenamic acid (SUCRA: 0.824) and ketoprofen (SUCRA: 0.781) followed. Combining these two primary outcomes, flurbiprofen was the most efficacious treatment in our result, and tiaprofenic acid was also a good treatment when took efficacy and safety into consideration. The ranking in secondary outcomes also revealed the excellent performance of these drugs. In addition, aspirin was considered to be the worst intervention because it ranked last among all the interventions except for placebo in most outcomes.

###### 

Surface under the cumulative ranking curve (SUCRA) results of six outcomes.

![](10.1177_1744806918770320-table5)

Note: The warm color represents a high SUCRA value, which also suggests a relatively high ranking.

Inconsistency test {#sec10-1744806918770320}
------------------

Node-splitting analysis of five outcomes for all the drugs is shown in [Tables 6](#table6-1744806918770320){ref-type="table"} and [7](#table7-1744806918770320){ref-type="table"}. A value of *P* less than 0.05 indicated that there was a significant inconsistency. As the results of the analysis show that there was no significant difference in the outcome of pain relief, additional rescue, pain intensity difference, and assessment. As for the outcome of adverse effects, inconsistency between flurbiprofen and aspirin (*P* = 0.012), as well as naproxen and flurbiprofen (*P* = 0.036), was found. The net heat plot results of consistency test are also shown in [Figure 3](#fig3-1744806918770320){ref-type="fig"} and Figures S6 to S9, which revealed the same result.

###### 

Node-splitting results of the network meta-analysis for three dichotomous outcomes.

![](10.1177_1744806918770320-table6)

  Outcomes                              Comparison                 OR (95% CrI)          *P*                                       
  ------------------------------------- -------------------------- --------------------- --------------------- ------------------- --------
  Pain relief                           Ibuprofen vs. placebo      5.30 (3.00, 9.80)     2.80 (0.41, 19.00)    5.50 (3.30, 9.20)   0.5200
  Ketoprofen vs. placebo                6.60 (2.90, 15.00)         4.30 (0.75, 26.00)    6.90 (3.70, 13.00)    0.6550              
  Naproxen vs. placebo                  5.10 (3.50, 7.70)          14.00 (4.10, 51.00)   5.70 (4.10, 8.50)     0.1150              
  Piroxicam vs. placebo                 29.00 (3.80, 260.00)       7.20 (1.50, 34.00)    11.00 (3.70, 42.00)   0.2663              
  Indomethacin vs. aspirin              3.80 (0.65, 17.00)         5.90 (1.30, 28.00)    4.80 (1.70, 14.00)    0.6425              
  Naproxen vs. aspirin                  5.80 (0.89, 35.00)         3.00 (1.30, 6.70)     3.20 (1.50, 7.00)     0.5188              
  Ibuprofen vs. diclofenac              0.76 (0.16, 3.30)          0.65 (0.14, 2.50)     0.87 (0.31, 2.30)     0.9000              
  Indomethacin vs. ibuprofen            0.87 (0.14, 4.70)          2.70 (0.69, 9.40)     1.60 (0.60, 4.60)     0.2913              
  Ketoprofen vs. ibuprofen              2.00 (0.58, 7.50)          0.94 (0.33, 2.70)     1.30 (0.58, 2.70)     0.3688              
  Mefenamic acid vs. ibuprofen          1.10 (0.22, 5.00)          1.80 (0.41, 7.00)     1.20 (0.43, 3.20)     0.6338              
  Naproxen vs. ibuprofen                2.00 (0.28, 12.00)         0.95 (0.51, 1.80)     1.00 (0.59, 1.90)     0.4413              
  Naproxen vs. ketoprofen               1.10 (0.35, 3.40)          0.60 (0.25, 1.60)     0.82 (0.41, 1.70)     0.4513              
  Tiaprofenic acid vs. mefenamic acid   1.80 (0.22, 17.00)         1.30 (0.18, 10.00)    1.60 (0.47, 6.00)     0.8063              
  Piroxicam vs. naproxen                1.30 (0.29, 5.80)          5.40 (0.62, 53.00)    2.00 (0.65, 7.30)     0.2850              
  Tiaprofenic acid vs. naproxen         1.70 (0.28, 10.00)         3.20 (0.49, 28.00)    1.80 (0.59, 5.80)     0.6088              
  Adverse effects                       Flurbiprofen vs. placebo   2.20 (1.00, 4.50)     0.75 (0.26, 2.00)     1.80 (1.00, 3.20)   0.0888
  Ibuprofen vs. placebo                 0.99 (0.53, 1.90)          0.67 (0.30, 1.50)     0.91 (0.57, 1.50)     0.4925              
  Ketoprofen vs. placebo                0.67 (0.30, 1.50)          1.80 (0.24, 14.00)    0.74 (0.36, 1.40)     0.3750              
  Naproxen vs. placebo                  1.10 (0.83, 1.40)          1.50 (0.75, 3.00)     1.10 (0.87, 1.30)     0.3500              
  Piroxicam vs. placebo                 0.90 (0.38, 2.10)          1.60 (0.53, 5.10)     1.10 (0.55, 2.20)     0.4275              
  Flurbiprofen vs. aspirin              3.10 (1.40, 6.70)          0.53 (0.15, 1.80)     1.90 (0.99, 3.50)     **0.0125**          
  Indomethacin vs. aspirin              2.50 (0.91, 6.80)          5.20 (1.20, 25.00)    3.70 (1.60, 8.30)     0.3913              
  Naproxen vs. aspirin                  0.61 (0.06, 4.40)          1.20 (0.66, 2.10)     1.10 (0.63, 2.00)     0.5225              
  Naproxen vs. flurbiprofen             1.40 (0.49, 4.00)          0.39 (0.20, 0.80)     0.60 (0.34, 1.10)     **0.0363**          
  Indomethacin vs. ibuprofen            6.30 (0.70, 180.00)        3.70 (1.40, 8.80)     4.00 (1.70, 9.40)     0.6863              
  Ketoprofen vs. ibuprofen              0.52 (0.09, 2.70)          0.95 (0.37, 2.50)     0.81 (0.35, 1.70)     0.5288              
  Mefenamic acid vs. ibuprofen          0.38 (0.10, 1.20)          1.20 (0.36, 4.00)     0.72 (0.31, 1.80)     0.1713              
  Naproxen vs. ibuprofen                1.60 (0.75, 3.40)          0.97 (0.52, 1.90)     1.20 (0.74, 1.90)     0.3150              
  Naproxen vs. ketoprofen               0.64 (0.06, 4.30)          1.70 (0.85, 3.80)     1.50 (0.72, 3.10)     0.3413              
  Tiaprofenic acid vs. mefenamic acid   0.63 (0.06, 4.30)          0.48 (0.02, 5.00)     0.69 (0.13, 3.00)     0.8838              
  Piroxicam vs. naproxen                1.50 (0.52, 4.20)          0.81 (0.31, 1.90)     1.00 (0.49, 2.10)     0.4000              
  Rofecoxib vs. naproxen                0.96 (0.41, 2.50)          0.83 (0.31, 2.20)     1.10 (0.57, 2.10)     0.8150              
  Tiaprofenic acid vs. naproxen         0.18 (0.01, 2.40)          0.55 (0.07, 3.30)     0.42 (0.08, 1.70)     0.5313              
  Additional rescue                     Flurbiprofen vs. placebo   0.12 (0.03, 0.49)     0.57 (0.10, 3.10)     0.25 (0.09, 0.71)   0.1638
  Ibuprofen vs. placebo                 0.10 (0.04, 0.26)          0.23 (0.05, 0.90)     0.14 (0.06, 0.29)     0.3200              
  Naproxen vs. placebo                  0.35 (0.23, 0.48)          0.11 (0.03, 0.44)     0.32 (0.21, 0.43)     0.1088              
  Flurbiprofen vs. aspirin              0.20 (0.05, 0.89)          0.62 (0.09, 4.40)     0.30 (0.09, 0.93)     0.3650              
  Naproxen vs. aspirin                  0.13 (0.01, 0.88)          0.45 (0.15, 1.20)     0.38 (0.14, 0.82)     0.2663              
  Naproxen vs. flurbiprofen             0.59 (0.12, 2.80)          2.40 (0.60, 9.60)     1.30 (0.42, 3.50)     0.1738              
  Naproxen vs. ibuprofen                1.30 (0.31, 5.70)          3.10 (1.10, 8.80)     2.30 (0.99, 5.40)     0.2875              
  Piroxicam vs. ibuprofen               1.70 (0.26, 18.00)         2.70 (0.39, 19.00)    2.00 (0.53, 7.30)     0.7175              

Note: Three dichotomous end points include pain relief, adverse effects, and additional rescue. Direct, indirect, or network odds ratios (ORs) and 95% credible intervals (CrIs) indicate the relative efficacy or safety. Bold values means *P*-value is smaller than 0.05, which indicated that there was significant inconsistency.

![Heat plots for pain relief. The size of the gray squares indicates the contribution of the direct evidence (shown in the column) to the network evidence (shown in the row). The colors are associated with the change in inconsistency between direct and indirect evidence. Blue colors indicate an increase in inconsistency, and warm colors indicate a decrease in inconsistency.](10.1177_1744806918770320-fig3){#fig3-1744806918770320}

###### 

Node-splitting results of the network meta-analysis for two continuous outcomes.

![](10.1177_1744806918770320-table7)

  Outcomes                              Mean difference                                                                     
  ------------------------------------- ----------------------- --------- ---------- --------- --------- --------- -------- -------
  Pain intensity difference             Ibuprofen vs. placebo   −1.2558   1.0796     −2.4998   1.6782    1.2440    1.9946   0.533
  Naproxen vs. Placebo                  −1.4379                 1.0737    −0.1431    1.6798    −1.2948   1.9926    0.516    
  Tiaprofenic acid vs. placebo          −0.3432                 1.8128    −3.5687    4.0633    3.2254    4.4491    0.468    
  Naproxen vs. flurbiprofen             0.9860                  1.7619    −16.6152   63.4955   17.6012   63.5210   0.782    
  Naproxen vs. ibuprofen                1.0838                  1.2938    −0.1717    1.5209    1.2556    1.9967    0.529    
  Tiaprofenic acid vs. mefenamic acid   −0.4577                 1.8129    2.7677     4.0631    −3.2254   4.4491    0.468    
  Assessment                            Aspirin vs. placebo     0.2518    0.6091     −1.5296   2.1541    1.7814    2.2388   0.426
  Ibuprofen vs. placebo                 0.6275                  0.4445    1.5780     1.6097    −0.9505   1.6704    0.569    
  Indomethacin vs. placebo              0.6747                  0.6239    0.4538     1.4531    0.2210    1.5815    0.889    
  Ketoprofen vs. placebo                0.9528                  0.6320    0.5631     1.8575    0.3897    1.9633    0.843    
  Naproxen vs. placebo                  0.6854                  0.3055    1.8207     2.2829    −1.1353   2.3033    0.622    
  Rofecoxib vs. placebo                 0.8675                  0.6165    0.8525     1.6429    0.0150    1.7561    0.993    
  Valdecoxib vs. placebo                0.6082                  0.8688    0.5697     1.6436    0.0384    1.8622    0.984    
  Indomethacin vs. aspirin              0.8192                  0.8590    −0.0481    1.1864    0.8673    1.4648    0.554    
  Indomethacin vs. ibuprofen            −0.4408                 0.8810    0.3675     0.9207    −0.8083   1.2745    0.526    
  Ketoprofen vs. ibuprofen              0.1405                  0.9008    0.3077     0.9797    −0.1672   1.3307    0.900    
  Rofecoxib vs. naproxen                −0.0010                 0.8642    0.3188     0.8571    −0.3198   1.2178    0.793    
  Valdecoxib vs. naproxen               −0.1140                 0.8685    −0.0756    1.6440    −0.0384   1.8622    0.984    

Note: Three continuous outcomes include pain intensity difference and assessment. Direct, indirect, or network results of standardized mean difference and standard error indicate the relative efficacy or safety.

Discussion {#sec11-1744806918770320}
==========

PD is a high-frequency female disease which will disturb the quality of normal lives of women.^[@bibr82-1744806918770320]^ NSAIDs are considered to be the first-line treatment for patients with PD; they are certain to be effective in relieving pain, but there is still no conclusion about the optimal choice in clinic.^[@bibr13-1744806918770320]^ Therefore, the objective of this network meta-analysis is to draw a conclusion about the optimal treatment within several types of NSAIDs through direct and indirect statistical analysis. Although only a small amount of studies in our database performed in the recent years, the results of our research were still meaningful since NSAIDs system has been developed a long time ago and maintained its crucial role in relieving PD in the last 30 years.

The results of our network meta-analysis suggested that all the drugs except aspirin were significantly more efficacious than placebo. However, there is no significant difference between each pair of NSAIDs concerning pain relief through direct evidence, which is consistent with the research by Marjoribanks et al.^[@bibr3-1744806918770320]^ In their research, they pointed out that NSAIDs were effective in relieving dysmenorrhea, whereas the sample size was too small to conduct a suitable meta-analysis for the comparison between two NSAIDs. Complementary to their results, the SUCRA ranking in our research provided the information of more efficacious treatments: flurbiprofen, piroxicam, and tiaprofenic acid. Naproxen was an analgesic that has been applied widely in many disease and showed significant relief of pain in PD in early time.^[@bibr38-1744806918770320]^ However, with the development of NSAIDs drugs, several other drugs have been illustrated as similar efficacy to naproxen.^[@bibr11-1744806918770320],[@bibr73-1744806918770320]^ In our result, naproxen was not significant efficacious compared to other NSAIDs drugs and showed an average efficacy in ranking.

As for the safety outcome, tiaprofenic acid and mefenamic acid were indicated as the safest NSAIDs drugs, while indomethacin was the worst one which was more likely to cause mild gastrointestinal discomfort. Naproxen, different from the research by Marjoribanks et al., was not reported with higher incidence of gastrointestinal side effects according to our network meta-analysis. Importantly, it is generally believed that selective COX-2 inhibitors, for example, rofecoxib and valdecoxib, are related with higher risk of serious cardiovascular disease with long-term usage.^[@bibr9-1744806918770320]^ Accordingly, our research demonstrated that the inferior performance of both rofecoxib and valdecoxib which were already announced withdrawal from the U.S. market in 2004 and 2005, respectively. Furthermore, it should be noted that flurbiprofen and tiaprofenic acid revealed good efficacy and were recommended to be the suitable choices for the patients with severe adverse effects. The safety ranking of flurbiprofen was not ideal in our results; however, the inconsistency of direct and indirect evidence was significant between flurbiprofen and naproxen as well as flurbiprofen and aspirin. Besides, there was only one trial having direct comparison of each pair. Thus, the relevant safety of flurbiprofen lacked enough credibility, and more researches are needed in the future.

Although the result of our network meta-analysis was relatively comprehensive, there were still several limitations which may affect the strength of each result. Firstly, even though the trials included in the research were various, the population employed was small scale (many trials included less than 100 people), and the reliability of the data was lightly weakened, especially in recommended NSAIDs like tiaprofenic acid (assessed in only 71 patients). Moreover, the availability and cost of these drugs have not been taken into consideration when they are regarded as recommended therapies. Secondly, we only evaluated the difference of efficacy and safety among NSAIDs but overlooked the dosage and frequency factor related to one drug. Also, we did not provide the optimal intake way of one single drug. Furthermore, previous studies have mentioned that the symptoms of PD were similar to the adverse effects of drug treatments which may also reduce the credibility of the results.^[@bibr63-1744806918770320]^ Thirdly, some included studies are pharmaceutically funded and may have risks of bias, though it can be adjusted with network meta-analysis method in some degree.

In conclusion, according to our network meta-analysis, we advocate flurbiprofen and tiaprofenic acid as the recommended NSAIDs therapies for patients with PD. Naproxen, as a well-established drug, did not show superior in efficacy or safety in our result. More efforts need to be made to further explore the characteristic of NSAIDs for PD patients.
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